CACCIOLA, Emma
 Distribuzione geografica
Continente #
NA - Nord America 14.604
AS - Asia 7.329
EU - Europa 6.701
SA - Sud America 1.335
Continente sconosciuto - Info sul continente non disponibili 500
AF - Africa 475
OC - Oceania 11
Totale 30.955
Nazione #
US - Stati Uniti d'America 13.909
SG - Singapore 4.080
RU - Federazione Russa 1.834
CN - Cina 1.828
IE - Irlanda 1.328
UA - Ucraina 1.265
BR - Brasile 1.078
IT - Italia 835
CA - Canada 547
VN - Vietnam 531
FR - Francia 451
KR - Corea 211
DE - Germania 204
NG - Nigeria 187
GB - Regno Unito 174
SE - Svezia 172
IN - India 160
CI - Costa d'Avorio 107
BD - Bangladesh 88
AR - Argentina 80
NL - Olanda 72
PL - Polonia 69
CH - Svizzera 57
MX - Messico 57
ZA - Sudafrica 52
TR - Turchia 48
EC - Ecuador 47
UZ - Uzbekistan 47
IQ - Iraq 44
FI - Finlandia 41
ES - Italia 39
JP - Giappone 39
HK - Hong Kong 37
CO - Colombia 34
VE - Venezuela 34
ID - Indonesia 31
KE - Kenya 29
PK - Pakistan 28
AT - Austria 21
SA - Arabia Saudita 21
EG - Egitto 19
GR - Grecia 19
JM - Giamaica 18
MA - Marocco 18
LB - Libano 17
SN - Senegal 17
BE - Belgio 16
CZ - Repubblica Ceca 16
PY - Paraguay 16
BJ - Benin 14
CR - Costa Rica 14
PE - Perù 14
RO - Romania 14
CL - Cile 13
LT - Lituania 13
TT - Trinidad e Tobago 13
BG - Bulgaria 12
TW - Taiwan 12
PH - Filippine 11
PT - Portogallo 10
IL - Israele 9
JO - Giordania 9
MY - Malesia 9
TN - Tunisia 9
UY - Uruguay 9
BY - Bielorussia 8
EU - Europa 8
IR - Iran 8
SV - El Salvador 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
BO - Bolivia 7
DZ - Algeria 7
NP - Nepal 7
DO - Repubblica Dominicana 6
HN - Honduras 6
KW - Kuwait 6
KZ - Kazakistan 6
LY - Libia 6
NI - Nicaragua 6
AZ - Azerbaigian 5
ET - Etiopia 5
PS - Palestinian Territory 5
AM - Armenia 4
GT - Guatemala 4
HR - Croazia 4
OM - Oman 4
SI - Slovenia 4
AL - Albania 3
BH - Bahrain 3
HU - Ungheria 3
KG - Kirghizistan 3
LV - Lettonia 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
PA - Panama 3
PR - Porto Rico 3
QA - Qatar 3
RS - Serbia 3
SY - Repubblica araba siriana 3
Totale 30.431
Città #
Dallas 2.544
Singapore 2.239
Dublin 1.325
Jacksonville 1.220
Santa Clara 1.204
Ashburn 1.107
San Jose 1.036
Chandler 954
Moscow 683
Boardman 526
Nanjing 422
Andover 367
Toronto 362
Cambridge 360
Lawrence 353
Lauterbourg 348
Hefei 247
San Mateo 229
Seoul 210
Chicago 206
Des Moines 203
Los Angeles 202
Beijing 170
Ho Chi Minh City 161
Catania 147
Wilmington 145
Nanchang 123
Hanoi 115
Abidjan 107
Lagos 103
New York 103
São Paulo 101
Hebei 98
Shenyang 95
Saint Petersburg 84
Buffalo 79
Council Bluffs 79
Ottawa 79
Grafing 77
Jiaxing 75
Civitanova Marche 73
Changsha 68
Abuja 66
Tianjin 66
Warsaw 53
Montreal 49
Piscataway 41
Milan 39
Rio de Janeiro 39
Bari 36
Orem 34
Phoenix 34
Seattle 34
Brooklyn 33
Tokyo 33
Denver 32
Hong Kong 32
Houston 32
Washington 32
Amsterdam 31
Atlanta 30
Dong Ket 30
Johannesburg 30
San Francisco 29
Boston 28
Bremen 28
Da Nang 27
Palermo 27
Quito 26
Kunming 25
Norwalk 25
Poplar 25
Pune 25
Redondo Beach 25
Munich 24
Stockholm 23
Tashkent 23
Den Haag 22
Chennai 21
Helsinki 21
London 21
Belo Horizonte 20
Mumbai 20
Curitiba 19
Hangzhou 19
Liberty Lake 19
Manchester 19
Newark 19
Ann Arbor 18
Baghdad 18
Brasília 18
Haiphong 18
Port Harcourt 18
Secaucus 18
Dakar 17
Brussels 16
Mexico City 16
North Bergen 16
Rome 16
Augusta 14
Totale 20.018
Nome #
Elevated fibronectin plasma levels in diabetes mellitus are expression of increased synthesis and release by vascular endothe- lium. 465
COVID-19 in Essential Thrombocythemia: Coagulopathy and Thrombosis 264
Correction to: Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research (Internal and Emergency Medicine, (2022), 17, 3, (887-909), 10.1007/s11739-022-02967-1) 226
Critical appraisal of the European Union Scientific Committee on Health, Environmental, and Emergency Risks (SCHEER) Preliminary Opinion on electronic cigarettes 219
Clinical appraisal of the European Union Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) Preliminary Opinion on electric cigarettes 208
Contributo delle piastrine reticolate alla generazione del fattore tessutale e del fattore di crescita trasformante-beta nella mielofibrosi primaria. Reticulated platelets contribution to tissue factor and transforming growth factor-beta generation in primary myelofibrosis. 191
B-linfociti CALLA (CD10) positivi nella leucemia linfatica cronica. 185
Activation of coaugulation and fibrinolysis in laparoscopic surgery 170
Thrombotic risk stratification in patients with prefibrotic myelofibrosis 168
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 161
Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea 156
A rare case of myeloid sarcoma presenting as anal fissure. 153
Activation of coagulation anf fibrinolysis in laparoscopic surgery 150
Adverse outcome in non severe COVID-19: potential diagnostic coagulation tests 150
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 150
A cause for conversion of laparoscopic splenectomy: splenic candidiasis 147
Laparoscopic surgery: A randomised controlled trial comparing intraoperative hemodynamic parameters and arterial-blood gas changes at two different pneumoperitoneal pressure values 146
Abnormal Erytropoietin serum levels in acute leukemia could have a role in the pathophysiology of disease. 146
Activation coagulation and fibrinolysis in laparoscopic surgery 146
Activation of contact phase of blood coagulation can be induced by the sclerosing agent polidocanol: Possible additional mechanism of adverse reaction during sclerotherapy 145
Acute COPD exacerbations cause alteration of the endothelium-coagulative system 141
Angiogenesis in essential thrombocythemia: fibroblast growth factor-2 and vascular endothelial growth factor cross-talk 139
Abnormal plasma levels of factor VIII/von Willebrand factor complex in myocardial infarction - Expression of acute phase reaction or index of va- scular endothelium damage? 138
Activated factor XII and thrombin activable fibrynolysis inhibitor levels in essential thrombocythemia and polycythemia vera 138
Hemocoagulative Modifications after Laparoscopic Surgery at Different Pneumoperitoneum Pressure Settings. 136
Alterations in ornithine decarboxylase and transglutaminase activities in lymphocytes from untrated patients with chronic lymphocytic leukemia. 136
Abnormalities of haemostatic balance in essential thrombocythemia and polycythemia vera 134
Surgical drain after open or laparoscopic splenectomy: is it needed or contraindicated? 131
All-trans retinoic (ATRA) induced apoptosis in pe- ripheral freshly isolated chronic myeloid leukemia cells. 131
Phase II randomized clinical trial comparing ropeginterferon versus phlebotomy in low-risk patients with polycythemia vera. Results of the pre-planned interim analysis. 131
Abnormal production of interleukin (IL)-6 in essential thrombocythemia. 128
Idiopathic intramural hematoma of the right colon. A case report and review of the literature. 127
Acute lymphoblastic leukemia in elderly. 126
Is it Still Reasonable to Raise Doubts on Laparoscopic Splenectomy? 126
Preoperative Predictive Factors of Conversions in Laparoscopic Splenectomies 124
D-dimer in the diagnostic work up of suspected pulmonary embolism: additional clinical value of PTP 123
. Trombospondin plasma levels in beta tha- lassemia:sickle cell disease 123
How to prevent intraoperative risks and complications in laparoscopic splenectomy 122
Label-Free Enrichment of Circulating Tumor Plasma Cells: Future Potential Applications of Dielectrophoresis in Multiple Myeloma 121
Laparoscopic cholecystectomy in adult patients with sicklecell disease. 121
"In vitro" hyperresponsivity of diabetic platelets to "saturated" platelet-activating factor (PAF). 120
Alteration of endothelium-coagulative system during COPD exacerbations 120
Hemocoagulative post-operative changes after laparoscopic surgery compared to open surgery: the role of lupus anticoagulant 119
Acquired antithrombin III deficency in sickle cell disease/beta plus thalas- semia. 119
Laparoscopic splenectomy: a single center experience 116
Il timing ottimale dell'introito di aspirina nella trombocitemia essenziale 112
Chronic idiopatic trombocytopenic purpura: is there any factor to predict the response to splenectomy? 112
Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms 110
Cessazione del fumo di sigaretta e riduzione dei livelli plasmatici di fattore di von Willebrand (vWF) 108
Late results after splenectomy in adult idiopathic thrombocytopenic purpura. 107
Long-term results after splenectomy in adult idiopathic thrombocitopenic purpura: comparison between open and laparoscopic procedures 106
Laparoscopic Splenectomy Reduces the Need for Platelet Transfusion in Patients With Idiopathic Thrombocytopenic Purpura 106
Study on the Anagrelide on Platelet Factor 4 and Vascular Endothelial Growth Factor Levels in Patients with Essential Thrombocythemia 106
Splanchnic vein thrombosis in JAK2V617F-positive patients with primary myelofibrosis and lower-risk IPSS. 105
Retroperitoneal paraduodenal unicentric Castleman disease: case report and review of the literature 105
betaFibrinigen G-455-A gene polymorphism: is it a factor for aspirin platelet insensitivity in patients with essential thrombocythemia? 105
The use of surgical drains in laparoscopic splenectomies. Consideration on a large series of 117 consecutive cases 104
Modification of coaugulation and fibrinolysic parameters in laparoscopic cholecystectomy 102
Laparoscopic splenectomy in patients under the age of eighteen. Experience in 18 cases. 101
In vitro sensitivity of B-CLL cells to Fludarabine and Interferons 101
Low dose of ARA-C in chronic myeloid leukemia in blastic transformation 100
The Antiphospholipid Syndrome 100
Sopravvivenza libera da trombosi in 734 pazienti con trombocitemia essenziale (WHO 2016) stratificati secondo lo score "Revised International Prognostic Score for Thrombosis in Essential Thrombocythemia (R-IPSET-Th)". Studio del Regostro ItalianoTrombocitemie (RIT) 100
Evidence for an aincreased fatty acid utilization in platelets in diabetes mellitus: its correlation withn platelet hyperfunction 99
I disordini dell'emostasi nelle emopatie maligne. 98
Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essentiial thrombocythemia: a preliminary report 98
Elevated plasma thrombopoietin levels and thrombosis in essential thrombocythemia: a preliminary report 97
Laparoscopic cholecystectomuy in adult patients with sickle cell disease 97
Essential thrombocythemia and fibroblast growth factor-2: role of anagrelide 97
Aspirin-platelet sensotivity in patients with essentila thtombocythemia: role of betafibrinogen G-455-A gene polymorphism 96
PEG Intron treatment in 90 patients with assential thrombocithemia (ET) final report of a phase II study 95
Polidocanol may directly activate the contact phase of blood coagulation during sclerotherapy 94
Alpha interferon as a first line therapy for angioimmunoblastic lympho- adenopathy. Possible value of DR+ cells in monitoring therapeutical re- sponse. 94
All-trans retinoic acid might also induce apoptosis in freshly isolated chro- nic myeloid leukemia cells 94
Splenic candidiasis : are perispelnic adhesions contraindications for laparoscopic splenectomy? 93
T-subset abnormalities in Thalassemia intermedia: Possible evidence for a Thymus functional deficiency. 93
B1-Integrin expression in adult acute lymphoblastic leukemia: Possible relationship with the stem cell antigen CD34 92
Immunomodulating treatment in patients with aplastic anemia. 92
Il mitoxantrone in polichemioterapia associato allo schema CVP nel trat- tamento dei linfomi non hodgkin. 92
Factor-VIII-rela- ted antigen and vasculitis. 91
Platelet factor 4, vascular endothelial growth factor and prothrombin fragment 1+2 levels in essential thrombocythemia treated with anagrelide 91
Effects of anagrelide on platelet and fibrinolytic function in patients with essential thrombocythemia 91
MECCANISMO DI ATTIVAZIONE PIASTRINICA NELLA TROMBOCITEMIA ESSENZIALE: RUOLO DEGLI ANTICORPI ANTI CELLULA ENDOTELIALE (AACE) 90
VLA-4 and VLA-5 integrin expression in adult acute lymphoblastic leukemia. 90
Unusual onset of severe varicella in adult immunocompromised patients 90
Persistent generalized lymphadenopathy (transfusion-related) in an HIV - seropositive heterosexual man with sckle-cell beta-tha- lassemia. 90
Le anemie carenziali. 89
Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis 89
B- chronic lymphocytic lekemia cells forming rosettes with sheep erythrocytes 89
Cardiovascular events and intensity of treatment in Polycythemia vera 89
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythemia vera (Low-PV study): a multicentre, randomised phase 2 trial 89
Low-dose cytarabine in myelodisplastic syndromes and acute leukemia: a comment 88
The antiphospholipid syndrome in pregnancy: a review article 88
Portal vein thrombosis after laparoscopic splenectomy: report on personal experience 88
Laparoscopic splenectomy reduces the need of platelet transfusion in patients operated on for idiopathic thrombocytopenic purpura 88
Thymostimulin in aplastic anaemia. 87
Role of FcR+ T-cells on the mechanism of the depressed polyclonal immunoglobulin synthesis in human mye- loma. 87
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 86
Trattamento preoperatorio con interleuchina-2 nel carcinoma colorettale. 86
Cutaneous vasculitis in non Hodgkin's Lymphoma. 86
Totale 12.209
Categoria #
all - tutte 109.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 109.620


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.311 0 387 21 30 429 5 394 92 282 5 63 603
2022/20233.474 365 93 28 229 348 652 4 576 971 29 115 64
2023/20241.666 81 110 73 86 65 160 160 355 17 40 230 289
2024/20255.265 38 716 369 170 1.183 404 110 201 517 689 313 555
2025/202612.713 704 595 2.641 779 2.097 2.043 1.838 295 661 553 257 250
2026/2027621 459 162 0 0 0 0 0 0 0 0 0 0
Totale 30.955